Неулептил

Quick links to important sections

Неулептил

Treatment option:

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Неулептил

Quick Facts

Property Description
Active ingredient Periciazine (Propericiazine)
Form Oral solution, Tablets, Capsules
Pharmacological class Neuroleptic Agent, Typical Antipsychotic
General purpose Management of severe emotional states and behavioral issues
Origin Synthetic

Неулептил: Active Ingredient and Pharmacological Class

Неулептил is a prescription-only medication whose active substance is Periciazine (also known as Propericiazine). This drug is fundamentally classified as a neuroleptic agent and is a member of the first-generation group of medicines, commonly referred to as typical antipsychotics. It is a synthetic compound derived from the phenothiazine class, specifically containing a piperidine group in its chemical structure. The drug's classification as a typical antipsychotic is characterized by its primary mechanism as an antagonist of dopamine receptors. This mechanism means the medicine is an option for addressing disturbances in mental processes requiring strong psychoactive support.


Forms, Composition, and General Therapeutic Aim

Periciazine is manufactured for oral administration in several forms, including an oral solution (often prepared as oral drops) and solid preparations such as tablets and capsules. The availability of the oral solution is a key differentiating factor, enabling precise titration for specific patient groups, including children aged five years and older, for whom accurate dosing is paramount. The general therapeutic aim of Неулептил relates to its core ability to exert a pronounced sedative effect alongside its antipsychotic action. This dual effect helps relieve symptoms associated with severe emotional states, targeting and reducing states of high pathologic arousal, intense tension, hostility, and disruptive impulsiveness. The medicine is utilized in managing these specific behavioral disturbances, aimed at stabilizing complex behavior and reducing severe agitation.


Summary of Core Identity and Type

Неулептил, with its active ingredient Periciazine, is fundamentally defined as a synthetic, single active ingredient product acting as a typical antipsychotic agent. Its established classification and forms ensure that it functions as a core medication for stabilizing mood and behavior in specific mental health contexts.

Regulatory References

  1. National Library of Medicine database

What side effects are possible with Неулептил?

Possible Side Effects and Safety Information

Неулептил (Periciazine) is associated with a range of side effects typical of a phenothiazine antipsychotic, affecting the nervous, cardiovascular, and metabolic systems. Effects are often most pronounced at the beginning of treatment or with prolonged use.


Adverse Reactions by System

System-Organ Class Common/Frequent Reactions Serious/Clinically Significant Reactions
Nervous System Drowsiness, dizziness, extrapyramidal symptoms (tremor, stiffness, restlessness) Neuroleptic Malignant Syndrome (NMS), Tardive Dyskinesia, Seizures
Cardiovascular Orthostatic hypotension (low blood pressure upon standing), Tachycardia (fast heart rate) QT Interval Prolongation, Torsades de Pointes, Sudden Death, Venous Thromboembolism (VTE)
Metabolic/Endocrine Weight gain, Hyperprolactinemia (can cause menstrual changes, breast enlargement), Hyperglycemia Severe hyperglycemia/Diabetes
Other Dry mouth, Constipation, Urinary retention, Photosensitivity Agranulocytosis (severe low white blood cell count), Cholestatic Jaundice, Paralytic Ileus

Safety Considerations and Restrictions

High-Risk Populations:

  • Elderly Patients with Dementia: Increased risk of cerebrovascular events (including stroke) and death, primarily due to cardiovascular or infectious causes. This medication is not approved for dementia-related psychosis.
  • Neonates: Use during the third trimester of pregnancy may result in withdrawal symptoms in the newborn (e.g., shaking, muscle rigidity, agitation, feeding difficulty).

Contraindications and Warnings:

  • The medication is contraindicated in patients with a history of agranulocytosis or blood dyscrasias, circulatory collapse, risk of angle-closure glaucoma, or urinary retention (e.g., from prostatic hypertrophy).
  • Patients with Parkinson's disease or existing cardiovascular conditions (e.g., heart failure, bradycardia, hypokalemia) require particular caution and close monitoring due to increased risk of side effects.
  • Routine blood monitoring is essential, especially during the first few months of treatment, to detect serious blood cell changes.

Overdose and Emergency Response

Overdose and when to seek help

If an overdose of Periciazine (Неулептил) is suspected, immediate medical attention is required due to the risk of serious and potentially fatal complications.

Overdose presentations typically affect the central nervous and cardiovascular systems, ranging from less severe manifestations to life-threatening conditions. Symptoms may include agitation, delirium, and confusion, progressing to lethargy or a comatose state. Observed neurological signs can involve twitching, dystonic movements, and convulsions. Severe cardiovascular effects include hypotension, arrhythmias, and cardiovascular collapse. General physiological signs such as hypothermia may also occur.

Overdose risk is increased when Periciazine is taken in combination with central depressant drugs, such as alcohol, hypnotics, or narcotics. In cases of overdose, immediate supportive treatment is essential.

Special Consideration: Neuroleptic Malignant Syndrome (NMS)

A potentially fatal symptom complex known as Neuroleptic Malignant Syndrome (NMS) is associated with antipsychotic drugs, including Periciazine. If signs of NMS are observed, the drug must be discontinued immediately. Management requires intensive symptomatic treatment, medical monitoring, and treating any serious concomitant medical issues. NMS is a medical emergency that requires urgent clinical intervention.

Neonatal and Infant Risks: Periciazine is contraindicated in children younger than one year due to a possible association with Sudden Infant Death Syndrome (SIDS). Neonates exposed during the third trimester of pregnancy are at risk for extrapyramidal and/or withdrawal symptoms after delivery.

Therapeutic Uses of Неулептил

What Неулептил Treats: Main Uses and Benefits

Неулептил (Periciazine) is a neuroleptic agent commonly used in the management of severe and disruptive symptoms associated with specific mental health conditions.

The medicine is relevant for easing symptoms within major domains, including the management of schizophrenia and other severe psychotic illnesses, the control of pronounced aggressiveness and impulsiveness, and the relief of severe tension and psychomotor agitation.

The indications for this medication are relevant in contexts involving heightened systemic burden, such as chronic and acute psychiatric contexts. It is applied across domains where additional symptomatic support is needed, such as in children aged five years and older to manage behavioral issues, and often used as adjunctive support for short-term management during acute episodes where symptoms are heightened.

“This therapeutic approach may assist with maintaining a sense of stability, and contributes to easing the overall symptom burden.”

This use supports patients during difficult episodes by easing distress and contributes to improved comfort during periods of heightened symptoms.


Quick Fact: Relief for Severe Behavioral and Affective Symptoms

Domain Targeted Symptom Categories Patient Benefit
Psychiatric Hallucinations, Delusions, Disorganized Thinking Contributes to easing the overall symptom burden.
Behavioral Aggressiveness, Hostility, Dangerous Impulsiveness Assists with maintaining functional stability.
Affective Severe Anxiety, Affective Tension, Agitation Relevant when supportive symptom management is appropriate.

Eligibility and Restrictions for Use

Who Can and Cannot Use Неулептил? (Periciazine)

The eligibility for using Неулептил (Periciazine) is strictly defined by regulatory documents, which outline who is permitted to use the medicine and who is absolutely prohibited.


Absolute Contraindications

Неулептил is contraindicated (must not be used) in several patient populations, including those with:

  • Severe Liver Disease or severe hepatic dysfunction.
  • A history of blood dyscrasias (e.g., agranulocytosis).
  • Acute states such as circulatory collapse or coma.
  • Known risk of angle-closure glaucoma or urinary retention due to urethroprostatic disorders.
  • Known hypersensitivity to periciazine or other phenothiazines.

Age-Based Eligibility

Age Group Eligibility Status
Children < 1 Year Contraindicated (Must not use)
Children 1–3 Years Not recommended for routine use
Children ge 5 Years Use is established for specific indications
Older Adults (Geriatric) Use requires caution and a lower initial dose

️ Conditional Use and Special Status

Use is not established and not recommended during pregnancy unless the benefit significantly outweighs the risk. The medicine should be avoided in patients with established renal dysfunction and used with caution in those with cardiovascular disorders (e.g., risk of QT prolongation). Neuroleptics are generally avoided in patients with Parkinson's disease.

What should I know about interactions with other medicines?

Contraindicated Combinations

The interaction profile for Periciazine (Неулептил) establishes certain combinations that are formally prohibited due to their high risk. Co-administration with Dopaminergic Antiparkinsonism Agents is contraindicated, as regulatory information documents a reciprocal antagonism that counteracts the effects of both medications. Furthermore, medicines that are known to prolong the QT interval are strictly contraindicated, including Class Ia and III anti-arrhythmics and specific antidepressants such as Citalopram and Escitalopram. This prohibition is in place due to a potentially severe and documented risk of ventricular arrhythmias.

Pharmacodynamic and Substance Interactions

Pharmacodynamic additive effects are noted when Periciazine is used alongside other substances that affect the central nervous system. Combining Periciazine with other CNS Depressants (including narcotics and certain antihistamines) or with alcohol results in a marked enhancement of sedation and impairment. There is also an increased risk of orthostatic hypotension when co-administered with Antihypertensive Agents, and a potentiation of anticholinergic symptoms with Anticholinergic Agents. Elderly patients are specifically noted as having a heightened susceptibility to these additive sedative and hypotensive effects.

Pharmacokinetic and Absorption Effects

Periciazine is subject to pharmacokinetic modification. Co-administration with strong CYP2D6 inhibitors may reduce its metabolism and cause an increase in the plasma concentration of Periciazine. Conversely, antacids containing aluminium or magnesium may reduce the absorption of Periciazine from the gastrointestinal tract, potentially lowering systemic exposure.

Mechanism of Action

️ How Неулептил Works

Periciazine (the active molecule in Неулептил) operates through a multi-target antagonism mechanism, binding to and blocking several key G-protein coupled receptors ( GPCRs) within the central nervous system (CNS).

Primary action involves the blockade of Dopamine D2 and Serotonin 5-HT 2A receptors. This dual antagonism modulates signaling within the mesolimbic pathway, resulting in the physiological adjustment of central psychoactive pathways and modifying dopaminergic outflow associated with excessive motor and emotional responses.

A defining characteristic is the molecule’s high affinity for Histamine H1 and Alpha1 (alpha1) Adrenergic receptors. The H1 antagonism initiates a rapid mechanistic cascade that directly suppresses the Reticular Activating System (RAS), resulting in central physiological depression and the suppression of CNS pathways that mediate arousal. The broad affinity profile, including alpha1 and muscarinic receptors, constrains the drug's mechanistic focus toward general CNS depression and modifies the regulatory function of the autonomic nervous system.

Dosage and Administration Information

General Principles of Administration

Неулептил (Periciazine) is administered exclusively by the oral route, available in solid dosage forms (tablets/capsules) and an oral solution or drops. The core administration strategy involves starting treatment with a low dose and progressively increasing the amount (titration) until the optimal level is reached, after which the dosage is adjusted to maintain control of symptoms. The total daily dosage is typically administered in divided portions, and the larger portion may be taken in the evening to mitigate certain effects. Tablets and capsules must be swallowed whole and should not be crushed, broken, or chewed. The oral solution is measured using the measuring dropper provided with the product.


Official Dosing Regimens and Adjustments

For adults with severe conditions, initial dosage levels are typically 75 mg per day in divided amounts, increasing by 25 mg per day at weekly intervals, and generally not exceeding a maximum of 300 mg per day. For mild or moderate conditions, the starting daily dose is lower, ranging from 15 mg to 30 mg total, divided into two doses. Dosing is adjusted for specific populations: older adults are started on substantially lower initial doses (e.g., 5 mg to 10 mg per day) and rarely require doses above 30 mg per day. Usage is generally restricted for those under five years of age.


Course Management

Treatment duration varies, with use for agitation and impulsiveness often intended as short-term management. If a dose is missed, the typical practice is to skip the missed dose if it is close to the time for the next scheduled dose, and not take two doses together. Importantly, the medicine is not stopped suddenly; the dosage is gradually reduced under supervision to conclude the treatment course.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Неулептил (Periciazine)


Evidence for use in Psychotic Disorders (e.g., Schizophrenia)

The evidence base for Periciazine in conditions such as schizophrenia is largely rooted in clinical research conducted between the 1960s and 1980s. These older studies included Randomized Controlled Trials (RCTs) that research examined the medicine in adults experiencing chronic or acute phases of schizophrenia. The original trials monitored outcomes related to overall global state and research explored how symptoms evolved during short-term follow-up intervals.

However, modern systematic reviews describes this evidence as Very Low quality because the original reports often lacked detailed information on trial methods. The small sample sizes and poor reporting led to findings were mixed, meaning clear conclusions were difficult to establish, and comparative evidence is lacking against most newer treatments.


Evidence for use in Severe Behavioral Disturbances

Periciazine was studied for its use in managing severe, disruptive symptoms, including aggressiveness, hostility, and impulsiveness. Research has explored this use in adults and also in children aged five years and older who have severe behavioral issues. The studies focused on outcomes monitoring episodic or acute phases of heightened symptom activity.

This research base is classified as Low quality, as the evidence is mainly historical or preliminary. Modern, large-scale RCTs designed to rigorously evaluate Periciazine's effect on aggression specifically are still emerging. Therefore, the data highlight what was observed in some studies during limited time intervals, but they do not determine whether an individual will respond similarly.


Evidence in Special Populations

The research evaluating Periciazine in specific patient groups is limited. The most significant subgroup where specific studies were evaluated is children aged five years and older dealing with severe behavioral disorders. These studies monitored outcomes related to disruptive behavior in this young population, noting the use of the oral solution form in the research setting.

Data for certain groups remain insufficient. Specifically, there is limited information available from dedicated research on older adults or individuals with complex comorbidities. The results apply only to the populations studied and do not provide broad context for individuals outside those trial parameters.


Long-term Studies and Evidence Durability

Research has focused primarily on research exploring short-term symptom changes. Follow-up durations were limited in most existing trials summarized by systematic reviews. Therefore, long-term effects are not fully established, and evidence is limited regarding the durability of any observed patterns or the medication’s potential role in long-term maintenance.


Quality of Evidence and Research Gaps

Overall, the clinical evaluation of Periciazine was observed in studies that often do not meet current methodological standards. The certainty remains low across both main indications due to high risk of bias and the fact that sample sizes were modest. The most significant research limitation frame is the age of the studies and the comparative evidence is lacking against most modern therapies. This means that the evidence highlights what is known under the specific conditions of those older trials, but it provides context but not individual predictions.

Frequently Asked Questions (FAQ)

Common questions about Неулептил (FAQ)

Q: What is the typical duration people stay on Неулептил?

The required duration of treatment with Неулептил is specific to the condition being addressed. Official regulatory documents indicate that for conditions involving severe anxiety or acute agitation, its use is typically intended for short-term management. However, for chronic conditions such as schizophrenia, the medicine is generally intended for long-term treatment, provided it is tolerated and clinically appropriate.

Q: Can Неулептил cause long-term side effects that won't go away?

Regulatory documents indicate that certain effects have been observed following prolonged therapy with this class of medicine, and some may potentially persist even after treatment is stopped. Examples of effects noted after extended use include Tardive Dyskinesia (uncontrollable movements), as well as possible retinal changes and abnormal skin pigmentation.

Q: Is Неулептил habit-forming or addictive?

According to official patient information, Неулептил is a neuroleptic medication and is not considered addictive or habit-forming.

Q: How does Неулептил affect driving or operating machinery?

Because the medicine can cause central nervous system effects, official warnings state that it may cause drowsiness, slower reaction time, and impaired judgment. Regulatory documents state that patients are generally cautioned against driving or operating machinery until they understand the medication's effect on their personal abilities.

Q: Is Неулептил sometimes prescribed for managing agitation or aggression?

Yes, regulatory documents list its use as an adjunct (additional therapy) in the short-term management of specific behavioral symptoms. These symptoms include psychomotor agitation, violent behavior, aggressiveness, and impulsiveness when associated with psychiatric conditions.

Q: What should I do if I experience a strange movement or twitch while taking Неулептил?

If a patient notices unusual or uncontrollable muscle movements, such as shaking or twitching (which are signs of extrapyramidal symptoms), contacting a healthcare provider is generally recommended. Such effects are described in official information and warrant discussion with a healthcare provider.

Q: Do research findings suggest any new potential uses for Неулептил?

While the medicine has specific, regulated indications, research has historically examined the use of periciazine in areas outside its main approved indications. For example, some studies have explored its potential in the treatment of opioid dependence.

Q: What are the most common reasons why a person might have to stop taking Неулептил?

The decision to stop the medicine is a complex clinical one. Reasons often involve a doctor determining when the potential risks outweigh the benefit of continued use, when a patient requires a switch to safer or more cost-effective alternatives, or in the event of certain severe adverse drug effects that necessitate discontinuation.

Q: Is it normal to experience vivid dreams or nightmares on Неулептил?

Adverse reaction reports documented in official regulatory sources list the occurrence of bizarre dreams. Nightmares or vivid dreams may be considered related to this type of psychiatric side effect.

Q: Do official documents mention any risk of allergic reactions to Неулептил?

Yes, official safety documents mention the possibility of hypersensitivity to the drug itself or to other drugs in the phenothiazine class. Should severe allergic symptoms like rash or swelling occur, official guidance states that immediate medical attention is necessary.

Q: Is Неулептил classified as a major or minor tranquilizer?

Although the term 'major tranquilizer' is an older, historical name for this drug class, Неулептил is officially classified as a neuroleptic agent. It belongs to the first-generation group of medicines, commonly referred to as typical antipsychotics.

Q: How does Неулептил affect appetite?

Regulatory reports indicate that this medicine may cause changes in appetite. Specific adverse reaction documentation lists both loss of appetite (anorexia) and, in other instances, increased appetite as possible effects.

Q: Does using tobacco products affect how Неулептил works?

Tobacco smoking has been observed to affect the metabolism of some similar antipsychotic medicines in the body, which could potentially lower their effective levels. If a patient smokes or stops smoking while using this medication, they are advised to discuss this change with their doctor.

Q: What does official guidance say about taking Неулептил with herbal products?

Official guidance emphasizes caution when combining prescription drugs with over-the-counter or herbal remedies. Official guidance suggests consulting with a pharmacist or healthcare professional regarding the use of herbal remedies alongside this medication.

Q: Can taking Неулептил make it difficult to regulate body temperature?

Adverse reaction reports mention the possibility of body temperature dysregulation and hyperthermia (high body temperature). These are potentially serious effects, as temperature changes are also key symptoms of Neuroleptic Malignant Syndrome (NMS).

Q: Is Неулептил commonly used for insomnia?

Insomnia (difficulty sleeping) is not a regulated indication for this medicine. Clinical guidance often describes its use strictly as a sleep aid as inappropriate or off-label, meaning it is not approved for that specific purpose.

Q: What is the risk of developing tardive dyskinesia from Неулептил?

Tardive Dyskinesia (TD), which involves involuntary movements, is a recognized, potentially serious risk with phenothiazine antipsychotics. Regulatory documents emphasize using the lowest effective dose for the shortest duration deemed necessary to help minimize this risk in all patients.

How should Неулептил be stored and disposed of?

How to Store and Dispose of Neuleptil (Periciazine)

The storage and disposal of Neuleptil must comply strictly with official regulatory requirements to ensure product stability and safety.

Storage Conditions

Neuleptil must be stored at controlled room temperature, specifically below 25°C (77°F), and must not be allowed to freeze. The medication requires protection from excessive heat, moisture, and direct sunlight to prevent degradation. As a mandatory safety measure, the product must be kept out of the reach and sight of children in a secure location.

Disposal Instructions

Unused or expired Neuleptil must be disposed of safely, typically through a local drug take-back program. If a take-back option is unavailable, the medicine should be mixed with an undesirable substance (like coffee grounds or dirt) and sealed in a container before disposal in the household trash. The medication must not be flushed down the sink or toilet.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Неулептил found in:

A-Z Index: